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1. Introduction  16 
Apoptosis has been considered as one of the main factors that may be related to loss of SG secretory function [1]. 17 
In fact, death of acinar and ductal cells is considered to be a major mechanism leading to salivary gland 18 
dysfunction in patients with SjÖgren’s syndrome [2] and following irradiation of salivary glands [3]. While 19 
apoptosis was classically described as an immunologically silent mode of cell death, several studies have shown 20 
that cells and tissues stimulated to undergo apoptosis produce moderate amounts of chemoattractant proteins and 21 
cytokines [4], indicating that apoptosis and inflammation are inseparably linked. Recent studies indicate that 22 
caspases, the initiators of the apoptotic cell death pathway, are  situated at the nexus of vital networks that balance 23 
inflammation, antiviral immunity and cell death [5].  24 
Caspases are a family of proteases that have been subdivided functionally into those involved in either apoptosis 25 
(caspases-2, -3, -6,-7, -8, -9 and -10 in mammals) or inflammation (caspases-1, -4, -5 and -12 in humans and 26 
caspases-1, -11 and -12 in mice) [6]. While the apoptotic caspases function in the initiation and execution of a 27 
programmed cell death, inflammatory caspases mediate innate immune responses by cleaving proinflammatory 28 
cytokine precursors (for example, pro-IL-1β and pro-IL-18) to initiate inflammation [7].  29 
Emerging studies have shown that caspase inhibition prevents inflammation via preventing T cell activation, Th2 30 
cytokine production and inflammatory cell infiltration [8]. More recent studies showed that pre-treatment with the 31 
cell permeable pan-caspase inhibitor z-Val-Ala-Asp (Ome) ﬂuoro-methyl-ketone (z-VAD-fmk), which 32 
irreversibly binds to the catalytic site of caspase proteases [9], significantly inhibited the activation of 33 
myeloperoxidase (MPO), TNF-α, IL-1β and decreased lung injury in a rat model of severe acute pancreatitis [10]. 34 
The role played by all mammalian caspases in the control of inflammatory and immune reactions has recently 35 
been thoroughly reviewed [11].   36 
Toll-like receptors (TLRs) are transmembrane pattern recognition receptors, which play key roles in sensing 37 
microbial pathogen associated molecular patterns (PAMPs) and mounting an immune response. Indeed, TLRs 38 
induce the expression of inflammatory pro-survival factors and cytokines [12], that recruit polymorphonuclear 39 
leukocytes (PMNs) to the infection site [13]. TLR3 has been identified as a key sensor for viral dsRNA or its 40 
synthetic double stranded (ds)RNA analogue poly (I:C) [14].  In turn, poly (I:C) can elicit apoptosis directly in a 41 
TLR3 dependent manner [15]. Despite the recent studies and reviews that propose caspases as the central 42 
regulators of apoptosis, inflammation and key effectors of immune responses against microbial infections [5,7,16-43 
19], it is unclear if caspases play an immune regulatory role during acute injury phases in vivo. In the current 44 
study, we stimulated the TLR3-mediated innate immune response of the C57BL/6 SMGs via the synthetic dsRNA 45 
poly (I:C). The induction of a caspase-dependent apoptotic signal in the glandular cells was substantiated as early 46 
as nine hours post poly (I:C) intraductal infusion. Moreover, pre-treatment of the mice with z-VAD-fmk, blocked 47 
the activated caspases and substantiated their participation in the TLR3-mediated innate immune signalling and 48 
cytokine production. 49 
Our results provide, for the first time, evidence that caspases are central in regulating inflammatory cell infiltration 50 
and activation of innate immune responses in vivo following TLR3 stimulation.  51 
 52 
  53 
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2. Materials and Methods 54 
2.1 Mice  55 
 56 
Female C57BL/6 mice weighing 18-21 grams (Harlan Labs Ltd., Loughborough, UK) and aged 10-12 weeks were 57 
housed in a temperature-controlled environment under a 12 h light–dark cycle, with free access to food and water. 58 
All procedures were approved by the local ethics committee and performed under general anaesthesia under a 59 
Home Office license. 60 
 61 
2.2 Poly (I:C) injury model 62 
The C57BL/6 mouse SMGs were cannulated as previously performed in rats [20] and mice [21].  Initially, a glass 63 
cannula (Supelco, 25715, PA- USA) was stretched over a flame and fitted into a polyethylene tube with 0.28 mm 64 
inner diameter. Polyinosinic–polycytidylic acid sodium salt (P1530-25MG, Sigma-Aldrich) was then diluted in 65 
0.9% saline solution to a final concentration of 4mg/ml. Towards consistent, visualised and flawless SMG 66 
injection, poly (I:C) was pre-mixed with Trypan blue (T8154-100ML-Sigma- Aldrich) prior to injection. Eighty 67 
micrograms of poly (I:C) in 20 µls were loaded into a 0.3 ml syringe (6134900, VWR International). For recovery 68 
experiments, mice were anaesthetised intraperitoneally (i.p) with 0.1 ml of combined 5 mg Ketamine/1 mg 69 
Xylazine. Under a stereomicroscope, the glass cannula was inserted into Wharton’s duct and poly (I:C) was 70 
injected slowly and constantly into the left SMG (Fig. 1A). The same volume of the vehicle (0.9% saline and 71 
Trypan blue) was delivered to the right SMG as a contralateral negative control. 72 
 73 
2.3 Assessment of Submandibular Secretory Function 74 
Animals were anaesthetized with 150 µl of Pentobarbital Sodium (Euthatal, Merial) 1 mg/ml (i.p.), followed by 75 
endotracheal intubation. Each submandibular duct was exposed by dissection from the ventral surface through the 76 
mylohyoid muscle. Individual submandibular ducts were cut and saliva was collected using polyethylene tubes 77 
connected to insulin syringes (Fig. 1B). Saliva collection proceeded for 5 min following onset of secretion after 78 
stimulation with pilocarpine (0.5mg/kg i.p.). Following collection into pre-weighed Eppendorf tubes, the tubes 79 
were re-weighed, the volume of saliva was calculated as 1mg = 1μl saliva and results were expressed as µL 80 
saliva/min. 81 
 82 
2.4 Z-VAD-fmk and apoptosis inhibition model 83 
Cell-permeable z-VAD-fmk (BD Pharmingen™, 550377) was dissolved in DMSO, aliquoted and stored at −80◦C, 84 
and then diluted as needed in PBS for experiments. Mice were pre-treated intraperitoneally with z-VAD-fmk 85 
(10mg/kg), 30 minutes prior to intraductal injection with poly (I:C) [22]. In the current study, this group will be 86 
referred to as z-VAD-fmk+PIC. The contralateral submandibular gland was injected with the vehicle (0.9% saline 87 
and Trypan blue). Tissues were excised and saliva was collected 9 hrs following poly (I:C) intraductal injection. 88 
 89 
2.5 TLR3/dsRNA complex inhibitor model 90 
The TLR3/dsRNA complex inhibitor ((R)-2-(3-Chloro-6-ﬂuorobenzo [b] thiophene-2 -carboxamido)-3-91 
phenylpropanoic acid, Calbiochem Merck Millipore, 614310) was used to competitively disrupt poly (I:C) binding 92 
to TLR3 [28].  The inhibitor was dissolved in DMSO and diluted in PBS. 1mg/mouse of the inhibitor was 93 
intraperitoneally injected into mice [23].  At the same time, 4µg/µl poly (I:C) was combined to 50 ng 94 
TLR3/dsRNA and 20 µl of this solution was loaded in a 0.3 ml syringe. Mice were anaesthetised as previously 95 
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mentioned and poly (I:C)-TLR3/dsRNA inhibitor were injected slowly and consistently into the SMG. In the 96 
current study, this group will be referred to as TLR3-I+PIC. The contralateral SMG was injected with the vehicle 97 
(0.9% saline, Trypan blue and 50 ng TLR3/dsRNA complex inhibitor). Tissues were excised and saliva was 98 
collected 9 hrs following poly (I:C) intraductal injection. 99 
 100 
 101 
2.6 Histopathologic Examination 102 
Harvested SMGs were fixed in 10% neutral buffer formalin, processed and embedded in paraffin for long term 103 
storage. Poly (I:C) induced histomorphometric changes and immune cell infiltration were examined using 104 
conventional H&E stain and contrasted versus the saline injected control glands.  105 
  106 
2.7 Immunohistochemical Analysis 107 
Three µm tissue sections were deparaffinized, rehydrated, and unmasked in a single step using Trilogy™ (Cell 108 
Marque, Rocklin, CA, 920P-06). To block endogenous peroxidase activity and non-specific background staining 109 
sections were incubated in 3% hydrogen peroxide solution for 20-30 minutes. To block all epitopes on the tissue 110 
samples and prevent nonspecific antibody binding, sections were incubated with 1% BSA in 1X TBS, pH7.6 for 111 
5 minutes. Primary antibody (Table 1) was applied at the appropriate working dilution overnight at 4°C followed 112 
by secondary antibody (Table 1) which was incubated for 60 mins at room temperature. Colour was developed 113 
for 5 mins in DAB solution (Pierce™ 34002) and slides were counterstained in Mayer haematoxylin and DPX-114 
mounted for light microscopy.  115 
 116 
 117 
 118 
                        Table 1 Antibodies used in immunohistochemical analysis 119 
 120 
 121 
 122 
 123 
 124 
 125 
 126 
 127 
 128 
 129 
 130 
 131 
 132 
 133 
 134 
 135 
 136 
 137 
 138 
 139 
 140 
 141 
 142 
 143 
 144 
 145 
 146 
 147 
Antibody 
Source & Catalogue 
Number 
Working Dilution 
anti-dsRNA  
SCICONS Budapest, 
Hungary, J2-1511 
1:1500 
Cleaved caspase-3 
R&D Systems, 
MAB835 
1:280 
MPO 
BosterBio, USA, 
PB9057 
1:1000 
Interleukin 6 (IL-6) Abcam, Ltd, ab83339 1:900 
iNOS 
Novus Biologicals, 
USA, NB300-605 
1:700 
Polyclonal Goat Anti-Rabbit 
Immunoglobulins-HRP 
Dako, P0448 1:200 
Polyclonal Goat Anti-Mouse 
Immunoglobulins- HRP 
Dako, P0447 1:100 
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2.8 Western Blotting 148 
Tissues stored in RNAlater® were retrieved, homogenized in cell lysis buffer (AA-LYS-10 ml- RayBiotech, Inc., 149 
Norcross, GA) plus protease inhibitor cocktail (1:10 dilution, Calbiochem, UK) using a FastPrep™ tissue 150 
homogenizer (MP Biomedicals Santa Ana, CA). Protein concentration was measured using the Qubit® protein 151 
assay kit (Q33211, Invitrogen™, UK) and Qubit® 3.0 Fluorometer (Q33216, Invitrogen™, UK) and a total of 152 
15-20 μg /lane of the different lysates were separated by SDS-PAGE on a 4-12% Novex polyacrylamide gel 153 
(Invitrogen, UK). Electro-transfer of proteins was done for 1 hour to 0.2 µm pore–size nitrocellulose membrane 154 
(1620112, Bio-Rad, UK) according to standard protocol (Invitrogen, UK, Paisley), followed by membrane 155 
blocking with 5% bovine serum albumin. Membranes were incubated at 4°C overnight with the appropriate 156 
antibody (Table 2) in blocking buffer then washed and incubated with the HRP conjugated anti-rabbit secondary 157 
antibody in blocking buffer at room temperature for 1 h. For signal development, an Enhanced 158 
Chemioluminescence substrate (ECL, GE Healthcare, UK) was prepared following the kit manufacturer's 159 
recommendations and applied over the membranes. Excess reagent was flicked and positive and negative protein 160 
expression was assessed and captured using ChemiDoc™ MP System (Bio-Rad, UK).  161 
 162 
 163 
                   Table 2 Antibodies used in western blot analysis 164 
 165 
 166 
 167 
 168 
 169 
 170 
 171 
 172 
 173 
 174 
 175 
 176 
 177 
 178 
 179 
 180 
 181 
 182 
 183 
2.9 qRT-PCR Analysis 184 
For qRT-PCR analysis, SMGs stored in RNAlater® (R0901-100ml, Sigma-Aldrich) were homogenized using 185 
FastPrep™ tissue homogenizer (MP Biomedicals Santa Ana, CA) and RNeasy® Micro Kit (74004, Qiagen) was 186 
used for total RNA extraction. RNA concentration as well as the A260/280 and A260/230 ratios were then 187 
measured with the NanoDrop ND-1000 Spectrophotometer (Thermo Fischer Scientific, Nottingham UK).  188 
iScript™ cDNA Synthesis kit (170-8890, Bio-Rad) was used to reverse transcribe 100 ng of extracted RNA. qPCR 189 
reactions (10 µl/well) were prepared by adding SsoAdvanced ™ Universal SYBR Green Supermix (172-5271, 190 
Bio-Rad), primers (PrimerDesign™, Ltd.) (Table 3) and cDNA template. Thermal cycling was performed using 191 
Corbett RotorGene 6000 System (Qiagen, UK). In all qRT-PCR experiments, relative gene quantification was 192 
assessed according to the "Delta Delta CT" (ΔΔCT) [24], where ΔΔCT= [Ct GOI Exp – Ct HKG Exp]-[Ct GOI 193 
Cal – Ct HKG Cal]: Ct: cycle threshold, GOI: gene of interest, Exp: poly (I:C)-injected glands, HKG: 194 
Antibody Source & Catalogue Number Working 
Dilution 
Cleaved Caspase 3 Novus Bio, NB100-56113 1:5000 
Cleaved Caspase 8 (Asp387) XP® Cell Signalling Technology, 
8592 
1:1000 
iNOS 
Novus Biologicals, USA, 
NB300-605 
1:1000 
IL-1β Boster, PA1351 1:3000 
Β-actin Sigma, A2228 1 μg/mL 
Polyclonal Goat Anti-Rabbit 
Immunoglobulins-HRP 
Dako, P0448 1:2000 
Polyclonal Goat Anti-Mouse 
Immunoglobulins- HRP 
Dako, P0447 1:1000 
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housekeeping gene showing the highest stability within each experiment condition, Cal: control glands injected 195 
by the vehicle. 196 
 197 
                          Table 3 Primers used in qRT-PCR assessment of gene expression 198 
 199 
 200 
 201 
 202 
 203 
 204 
 205 
 206 
 207 
 208 
 209 
 210 
2.10 PCR Array of Mouse Toll-Like Receptor Signaling Pathway 211 
To analyse the signalling pathway downstream of TLR3 ligation in SMGs from z-VAD-fmk treated and non-212 
treated animals, the mouse RT² Profiler Toll-Like Receptor (TLR) signaling pathway array was used. RNA was 213 
extracted as previously mentioned and 800 ng was reverse transcribed using the RT2 First Strand Kit (330401, 214 
Qiagen), according to the manufacturer’s protocol. Twenty µl of the PCR reaction mix (Table 4) was added to 215 
individual wells of the RT2 Profiler PCR array format R (PAMM-018ZR, Qiagen) and the thermal cycler was set 216 
according to http://www.SABiosciences.com/pcrarrayprotocolfiles.php.  217 
 218 
 219 
                              Table 4 qRT-PCR reaction mix 220 
2x RT2 SYBR Green ROX FAST Mastermix (330520, Qiagen) 1150 µl 
cDNA synthesis reaction 102 µl 
RNase-free water 1048 µl 
Total Volume 2300 µl 
 221 
 222 
A threshold value above the background signal was chosen and the CT values for the run samples were extracted 223 
to an excel sheet and analysed using the web-based PCR Array Data Analysis Software available at 224 
www.SABiosciences.com/pcrarraydataanalysis.php. Altered expression was assessed by comparing poly (I:C) 225 
treated glands with their contralateral vehicle-injected control glands, from mice treated and non-treated with z-226 
VAD-fmk. 227 
 228 
 229 
2.11 Digital image analysis of cleaved caspase-3 and MPO-immunopositive cells 230 
In each tested group, fifteen random high magnification fields (five from three independent experiments) were 231 
captured and colour images of 640 × 480 pixel resolution were then analysed by semi-quantitative digitalized 232 
image analysis using ImageJ, NIH ® [25]. Briefly, images were transformed by threshold mode to locate the 233 
positive immunostained area, then converted to 8-bit images in grey scale. Subsequently, the area percentage of 234 
Gene Accession Number 
TLR3 NM_126166 
Mx1 (Mx dynamin-like GTPase 1) NM_010846 
ISG-15 (ISG15 ubiquitin-like modifier) NM_015783 
IL 6 NM_031168 
IL 1β NM_008361 
HPRT (Hypoxanthine guanine phosphoribosyl transferase) NM_013556 
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) NM_008084 
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positive immunostaining was calculated by the area fraction command within measuring mode, which was 235 
expressed as the percentage of red pixels/SMG tissue section. 236 
 237 
2.12 Statistical analysis 238 
Results were shown as mean ± SEM (standard error of means). Statistical significance between individual 239 
comparisons was determined using Student t-test. For multiple comparisons, one-way ANOVA with Sidak’s 240 
(selected pairs) pairwise tests were used. In addition, Dunnett test was performed for comparing treatment groups 241 
with the control group. The calculations were performed with the statistical software package GraphPad Prism 242 
(version 7). P values ≤ 0.05 were considered statistically significant. 243 
  244 
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3. Results  245 
3.1 Poly (I:C) internalization and TLR3 upregulation.  246 
To visualize poly (I:C) internalization, a dsRNA monoclonal antibody was used to track its fate post retrograde 247 
injection into the SMG duct. The vehicle-injected SMGs did not show any dsRNA-positive signal. Conversely, 248 
the ducts and acini of the poly (I:C)-injected SMGs showed retention of poly (I:C) up to 24 hrs following its 249 
injection (Fig.1C). Next, qRT-PCR was performed and revealed that poly (I:C) induced the transcriptional 250 
upregulation of TLR3 in the SMGs. Immunohistochemical staining was performed in order to identify cell 251 
phenotypes expressing the activated receptor. Basally, TLR3 showed intense membranous and cytoplasmic 252 
immunostaining in the intercalated ducts. Following poly (I:C) introduction, TLR3 showed immunopositivity in 253 
the basolateral membranes of acinar and duct cells with increased numbers of intensely stained intercalated ducts 254 
(Fig. 2A). 255 
 256 
3.2 z-VAD-fmk blocked casp-8/csp-3 activated signals induced by TLR3 stimulation 257 
Mice were pre-treated with the TLR3/dsRNA complex inhibitor, which competitively inhibits dsRNA binding to 258 
TLR3 and immunohistochemistry was performed to explore the role played by TLR3 in caspase activation. A 259 
single poly (I:C) dose induced an extremely significant increase in the percentage of glandular epithelial cells 260 
expressing the apoptotic marker: cleaved caspase-3, compared to the vehicle injected control and the TLR3-261 
inhibited glands (p<0.0001) (Fig. 2B). In another set of experiments, mice were pre-treated with 10 mg/kg z-262 
VAD-fmk intraperitoneally, 30 minutes prior to intraductal minfusion of poly (I:C). Subsequently, SMGs were 263 
harvested and analysed by western blot to confirm blockade of the TLR-3-triggered apoptotic signal. Results 264 
obtained from these experiments confirmed that z-VAD-fmk pre-treatment interfered with expression levels of 265 
the TLR3-activated subunits of caspase-8/-3 in the poly (I:C)-injected glands (Fig. 3A). In addition, 266 
immunohistochemistry, showed downregulated expression of cleaved caspase 3 in the SMGs of the z-VAD-fmk 267 
treated animals, compared to those which received poly (I:C) only (Fig. 3B). 268 
 269 
3.3 z-VAD-fmk inhibited infiltration of TLR-3-recruited, MPO-positive, acute inflammatory cells 270 
 271 
H&E sections from SMGs of the control, poly (I:C)-injected, TLR-3 blocked and z-VAD-treated mice were 272 
microscopically examined and revealed that the poly (I:C)-infected glands from both the z-VAD treated and TLR-273 
3-inhibited mice were inflammation- and oedema-free; two hallmark features of the glands injected with poly 274 
(I:C) alone (Fig. 4). Next, the anti-inflammatory effect of z-VAD in the poly (I:C) infected glands was verified 275 
by immunolabelling tissues with the acute inflammatory marker: MPO (expressed in lysosomes of monocytes and 276 
azurophilic granules of neutrophils) [26] and comparing the results to those in the TLR3/dsRNA blockade model. 277 
Immunohistochemistry similarly confirmed the H&E results, whereby the SMGs from the poly (I:C) treated mice 278 
displayed many MPO positive immune cells, which were absent from the z-VAD- or TLR3-inhibitor-treated mice.   279 
(Fig .4).  280 
 281 
 282 
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3.4 Effect of z-VAD-fmk on pilocarpine stimulated saliva secretion 283 
 284 
To rule out induction of necroptotic cell death, which is coupled to caspase inhibition [17], the viability of the 285 
secretory parenchymal cells was assessed by exploring the functional response of the SMGs to pilocarpine 286 
stimulation. Blockade of active caspases using the z-VAD-fmk inhibitor preserved SMG secretory capacity, which 287 
had clearly deteriorated 9 hrs post intraductal infusion of poly (I:C). Similar functional protection was conferred 288 
by competitively blocking TLR3 (Fig. 5). 289 
 290 
3.5 Pan caspase inhibition interfered with transcriptional activation of TLR-related and interferon (IFN) 291 
stimulated genes 292 
 293 
The mouse RT2 Profiler™ TLR PCR array of 84 TLR-related innate immune adaptor and effector genes was used 294 
to broadly analyse SMG response to blockade of the caspase system by z-VAD-fmk. Intriguingly, pre-treating 295 
mice with z-VAD-fmk prior to poly (I:C) injection, reduced the expression level of all TLR-related genes, 296 
compared to their extensive transcriptional upregulation in the SMGs which received the innate immune stimulant 297 
only (Fig. 6A). In addition, specific primers for interferon-responsive genes were used to confirm this novel, 298 
negative feedback mechanism executed by caspase inhibition with z-VAD-fmk (Fig. 6B).   299 
 300 
Table 5a.   Fold change in the expression of mRNA of TLR-related genes, 6 hrs following poly (I:C) injection.  mRNA 301 
expression was assessed using an RT² Profiler Toll-Like Receptor (TLR) signaling pathway array. 302 
Layout 1 2 3 4 5 6 7 8 9 10 11 12 
A Agfg1 Btk Casp8 Ccl2 Cd14 Cd80 Cd86 Cebpb Chuk Clec4e Csf2 Csf3 
 7.75 3.59 11.84 119.02 28.94 8.78 33.59 -1.12 15.08 55.91 10.7 22.86 
B Cxcl10 Eif2ak2 Elk1 Fadd Fos Hmgb1 Hras Hspa1a Hspd1 Ifnb1 Ifng Ikbkb 
 522.76 8 1.84 2.6 5.46 16.51 3.57 19.16 9.85 445.72 37.01 2.53 
C Il10 Il12a Il1a Il1b Il1r1 Il2 Il6 Il6ra Irak1 Irak2 Irf1 Irf3 
 8.2 3.05 82.71 70.03 -1.27 1.38 364.56 2.43 4.72 2.9 16.8 6.02 
D Jun Lta Ly86 Ly96 Map2k3 Map2k4 Map3k1 Map3k7 Mapk8 Mapk8ip3 Mapk9 Muc13 
 3.56 3.67 5.66 8.78 4.45 3.59 2.22 2.57 3.88 1.38 3.84 12.04 
E Myd88 Nfkb1 Nfkb2 Nfkbia Nfkbib Nfkbil1 Nfrkb Nr2c2 Peli1 Pglyrp1 Ppara Ptgs2 
 4.08 17.15 9.13 19.7 3.32 1.24 1.93 5.62 7.16 18.83 -1.27 8.43 
F Rel Rela Ripk2 Tbk1 Ticam1 Ticam2 Tirap Tlr1 Tlr2 Tlr3 Tlr4 Tlr5 
 11.55 4.99 41.36 9.71 1.09 1.39 2.52 10.37 12.34 75.06 3.61 1.27 
G Tlr6 Tlr7 Tlr8 Tlr9 Tnf Tnfaip3 Tnfrsf1a Tollip Tradd Traf6 Ube2n Ube2v1 
 9.32 4.07 3.29 2.32 10.2 23.43 1.82 1.9 8.31 2.69 6.77 11.27 
 303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
 311 
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 312 
Table 5b Fold change in the expression of mRNA of TLR-related genes 6 hrs following z-VAD-fmk pre-treatment and poly 313 
(I:C) injection.  mRNA expression was assessed using an RT² Profiler Toll-Like Receptor (TLR) signaling pathway array. 314 
 315 
Layout 1 2 3 4 5 6 7 8 9 10 11 12 
A Agfg1 Btk Casp8 Ccl2 Cd14 Cd80 Cd86 Cebpb Chuk Clec4e Csf2 Csf3 
 1.2 1.27 1.48 4.03 2.17 1.48 2.33 -1.01 1.54 8.94 -1.34 18.51 
B Cxcl10 Eif2ak2 Elk1 Fadd Fos Hmgb1 Hras Hspa1a Hspd1 Ifnb1 Ifng Ikbkb 
 3.78 1.1 1.12 -2.04 1.13 1.26 1.06 1.82 -1.71 5.19 2.2 -1.07 
C Il10 Il12a Il1a Il1b Il1r1 Il2 Il6 Il6ra Irak1 Irak2 Irf1 Irf3 
 2.7 1.53 4.2 23.59 1.01 -1.02 4.58 -1.34 -1.08 -1.13 -1.05 1.11 
D Jun Lta Ly86 Ly96 Map2k3 Map2k4 Map3k1 Map3k7 Mapk8 Mapk8ip3 Mapk9 Muc13 
 -1.05 1.12 -1.12 2.13 1.06 1.02 -6.63 -1.31 -1.07 -1.32 -1.72 1.29 
E Myd88 Nfkb1 Nfkb2 Nfkbia Nfkbib Nfkbil1 Nfrkb Nr2c2 Peli1 Pglyrp1 Ppara Ptgs2 
 -1.62 1.55 1 -1.02 2.62 1.09 -1.24 1.02 1.06 3.05 -1.73 2.19 
F Rel Rela Ripk2 Tbk1 Ticam1 Ticam2 Tirap Tlr1 Tlr2 Tlr3 Tlr4 Tlr5 
 -1.3 1.08 -1.18 -1.9 1.12 1.01 -1.22 -3.72 1.13 1.04 1 -2.03 
G Tlr6 Tlr7 Tlr8 Tlr9 Tnf Tnfaip3 Tnfrsf1a Tollip Tradd Traf6 Ube2n Ube2v1 
 1.03 -1.76 -1.72 -1.22 3.13 2 -1.55 1.08 1.25 2.24 1.13 1.01 
 316 
 317 
3.6 Caspases are central in regulating the expression of TLR-3-induced pro-inflammatory cytokines 318 
 319 
To further define the immune regulatory functions of caspases, we investigated their potential contribution to 320 
cytokine production in response to TLR-3 stimulation. SMGs from the TLR3-inhibited and z-VAD-fmk-treated 321 
mice exhibited a dramatic decline in the transcriptional activation of the pleotropic cytokines, IL-6 and IL-1β 322 
compared to the vehicle injected control glands (Fig. 7A & B). In addition, protein levels of the activated IL-1β 323 
isoform (Fig. 7B) and inducible nitric oxide synthase (iNOS) were greatly diminished in parenchymal cells, 324 
following ductal injection with poly (I:C) (Fig. 7C).  325 
 326 
 327 
 328 
 329 
 330 
 331 
 332 
 333 
 334 
  335 
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4. Discussion 336 
The current study provides in vivo evidence that caspases regulate the TLR3-activated innate immune response. 337 
This conclusion is consistent with the important role played by caspases in coordinating and integrating signals 338 
that result not only in apoptosis but also inflammation and immune regulation [27]. Previous studies demonstrated 339 
that multiple, systemic injections of poly (I:C) into Sjӧgren’s syndrome-prone, NZB/WF1 mice, resulted in loss 340 
of glandular function [28,29]. The TLR3-stimulant in the current model was locally injected into the SMGs to 341 
avoid systemic delivery, which is more likely to dilute the poly (I:C) and minimize the chance of its efficient 342 
exposure to salivary parenchymal cells. Moreover, the model presented herein, is unique in demonstrating the 343 
direct influence of innate immune activation on the SMG tissues and functional responses, ruling out possible 344 
extraneous impacts arising either from systemic delivery or autoimmune susceptibility of mice. The cannulation 345 
technique established, enabled the development of a reliable and reproducible mouse model, whereby intraductal 346 
conveyance of poly (I:C) pre-mixed with Trypan blue allowed consistently successful infusion and delivery of the 347 
same amount of inflammagen into the SMGs (even when other drugs such as TLR3/dsRNA inhibitor and z-VAD-348 
fmk, were used). Parenchymal exposure to poly (I:C) and its efficient internalization into the SMG ductal and 349 
acinar cells were verified using the J2 monoclonal antibody which specifically recognizes dsRNA of more than 350 
40 base pairs in length [30]. The J2 antibody positively stained acinar and ductal cells which internalized the poly 351 
(I:C) and revealed that parenchymal cells retain the inflammagen up to 24 hrs post inoculation.  352 
The involvement of TLR3 in dsRNA-triggered apoptosis has previously been demonstrated by RNA interference 353 
[15,31]. Upon ligand recognition, TLR3 recruits the adaptor protein TRIF, which then interacts with the receptor 354 
interacting protein 1 (RIP1), a serine/threonine kinase that not only enhances survival through NF-κB and MAPK 355 
activation, but also promotes apoptosis by recruiting FADD and by activating caspase-8 [32]. Activated caspase-356 
8 cleaves and activates caspase-3, which then executes the apoptotic program [33]. Intraductal infusion of the poly 357 
(I:C) into the SMGs prompted transcriptional upregulation of TLR3, which triggered the expression of activated 358 
forms of caspase-8 and caspase-3. Cleaved caspase-3-positive duct and acinar cells were observed as early as 9 359 
hrs after poly (I:C) administration and were significantly decreased in the mice treated with the pan caspase 360 
inhibitor z-VAD-fmk. Surprisingly, systemic injection of z-VAD-fmk before challenging the SMG innate immune 361 
response, interfered with acute inflammatory cell infiltration and protected the SMG secretory machinery from 362 
the poly (I:C)-induced loss of function. z-VAD-fmk has shown therapeutic efficacy in many diseases including 363 
neurogenic pulmonary edema [34], muscle ischemia-reperfusion injury [35] and allergic lung inflammation [8].  364 
Caspases are closely inter-connected with cytokines and cytokine receptors, in that some caspases are essential 365 
for cytokine maturation (i.e. activation) and secretion. Caspase-1 cleaves pro-IL-1β and pro-IL-18 to the mature 366 
cytokine forms [36]. In addition, caspase-3 is involved in the processing of pro-IL-16 to the mature cytokine [37]. 367 
It has been previously shown that z-VAD-fmk inhibition of caspase-3 led to the down-regulation of JNK/SAPK 368 
and NF-kB, which were required for LPS-induced iNOS expression and NO production [38]. Moreover, caspase-369 
8 has been reported to directly cleave pro IL-1β into its mature, active form following TLR3/TLR4 stimulation 370 
[39], in addition to its direct activation of the inflammatory caspase-1, in an inflammasome-independent manner 371 
[40]. IL-1β can recruit a cascade of events downstream of the IL-1R complex, resulting in the activation of 372 
important signalling proteins, such as mitogen-activated kinases (JNK, p38, ERK1/2), as well as transcription 373 
factors, including NFκB (p65 and p50 subunits) and c-Jun (a subunit of AP-1), which control expression of a 374 
number of inflammatory and catabolic genes [41]. Whether TLR3 engages caspases for maximal cytokine 375 
production is not known, but the broad anti-inflammatory effect provided by z-VAD-fmk in the current injury 376 
model may have been down to its ability to inhibit caspases that cleave pro-IL-1β into its active form. 377 
In addition to their apoptotic roles, a new paradigm for caspases in non-apoptotic roles has become clear. In the 378 
current study, the pan caspase inhibitor, z-VAD-fmk negatively regulated the expression of an array of TLR-379 
related and IFN-stimulated genes. This finding may be due to the pleiotropic role of caspase-8 in the control of 380 
gene expression downstream of TLR stimulation [42], via: (i) induction of mRNA transcription and promotion of 381 
mRNA stability [17], (ii) localization to nuclei, raising the possibility that nuclear caspase-8 might play a role in 382 
gene expression [43] and (iii) regulating the activation of the transcription factor NF-κB [42,44-46], which induces 383 
the expression of target genes, including cytokines, chemokines, and adhesion molecules [47].  384 
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IFNs contribute to immune protection through the induction of cellular antimicrobial programmes and through 385 
enhancing immune responses for the efficient termination of infection [48]. However, type-I-IFNs can also be 386 
harmful, either by inducing immunosuppressive effects that impede viral control [49] or by triggering 387 
inflammation and tissue damage that exacerbate disease [50]. The results from arrays in the present study show 388 
very remarkable downregulation of the poly (I:C) induced Ifnb1 from 445 folds to 5 folds, when mice received 389 
the pan caspase inhibitor prior to poly (I:C). To confirm this novel and therapeutically significant finding, qRT-390 
PCR was carried out to further analyse the mRNA expression levels of IFN-response genes in poly (I:C) treated 391 
SMGs from the z-VAD-fmk treated and non-treated mice. Results from these experiments confirmed the array 392 
finding and revealed for the first time that caspase inhibition can potentially control unruly type I IFN-regulated 393 
genes. However, the mechanism(s) by which caspases directly or indirectly regulate the IRF-pathway in SMGs 394 
has not previously been addressed. Thus, further studies are needed to determine the importance of caspases for 395 
IRF signalling in response to TLR agonists in vivo. 396 
In conclusion, the current study is the first to demonstrate that the broad-spectrum caspase inhibitor z-VAD-fmk 397 
can regulate TLR3-induced gene expression and cytokine production in vivo, during the early stages of innate 398 
immune activation and inflammation. 399 
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Figure Legends 522 
Fig 1 Poly (I:C) retrograde ductal injection and saliva collection. A: Microscopic depiction of pre-fabricated glass 523 
cannula inserted into the sublingual papilla of Wharton’s duct for poly (I:C) delivery. B: Extraoral saliva 524 
collection. Mylohyoid muscle slits enclosed the accumulated saliva, that was withdrawn using polyethylene tubes 525 
attached to 0.3 ml syringe. C: Negative J2 immunolabelling of poly (I:C) in the vehicle-injected glands (V-C). 526 
Six hrs post poly (I:C) injection, the synthetic dsRNA was immunolocalized in the perinuclear areas of the duct 527 
cells (green outline and arrows) as well as the basolateral membranes of acinar cells (yellow outline and arrows), 528 
whereas after 24 hrs, more dispersed and less immunostaining intensity of poly (I:C) was detected in duct cells as 529 
well as acinar cells. Original magnification= 40x. 530 
Fig 2 A: Expression of TLR3 in the SMGs. Left: Transcriptional upregulation of mTLR3 in the SMGs, 6 hrs post 531 
poly (I:C) injection (6h P-PIC). Data represent means ± SEM (n=3). ****p≤0.0001. V-C: vehicle injected control, 532 
HPRT: Hypoxanthine guanine phosphoribosyl transferase (housekeeping gene). Right: immunoexpression of the 533 
dsRNA sensor. V-C: basal TLR3 expression in intercalated duct cells (arrow). P-PIC: after poly (I:C) injection, 534 
intense membranous and cytoplasmic positivity of intercalated ducts (yellow arrow) as well as mild basolateral 535 
staining of the acinar cells (red arrow). B: Immunohistochemical expression of cleaved caspase-3 in the ductal 536 
(yellow arrow) and acinar (red arrow) cells, 9 hrs P-PIC. Original magnification= 40x. Image analysis 537 
demonstrated that poly (I:C) remarkably induced the apoptotic signal in the SMGs in a TLR3 dependent manner. 538 
ns: non-significant p>0.05, ****p<0.0001. 539 
Fig 3 A: Western blot representation of caspase-8 and caspase-3 in the SMGs, 9 hrs P-PIC. Poly (I:C) induced 540 
caspase activation in a TLR-3-dependent manner. The protein products of caspase-8 and caspase-3 extracted from 541 
three independent vehicle (V-C), poly (I:C) (P-PIC) injected, TLR3-blocked (TLR3-I+PIC) and caspase-inhibited 542 
(z-VAD-fmk+PIC) SMGs, were measured by Western blot analysis. Bars represent the fold change in protein 543 
levels of activated subunits of caspase-8 and caspase-3, on the basis of β-actin and indicate mean values ± SEM 544 
(n = 3 in each group). ns: non-significant, ***P<0.001, ****p<0.0001 significant differences between the V-C 545 
and tested groups. B: Immunohistochemical expression of cleaved caspase-3 in SMGs from z-VAD-fmk-treated 546 
and non-treated mice, 9 hrs P-PIC introduction.  547 
Fig 4: H&E and MPO-immunostained sections demonstrating control and poly (I:C)-injected SMGs. The SMGs 548 
which received the carrier vehicle (V-C) showed normal histology in the form of packed acini and patent ducts.  549 
By 9 hrs, the poly (I:C)-infected glands (P-PIC) exhibited widespread infiltration of MPO-positive immune cells 550 
in extended stromal spaces, obscuring interlobular ducts and invading inter-acinar tissues. Very few MPO-positive 551 
immune cells were detected in the TLR3-blocked (TLR3-I+PIC) and z-VAD-fmk-treated animals (z-VAD-552 
fmk+PIC). Original magnification H&E=25x, MPO=40x. Bars represent area percentage of MPO positive cells 553 
in the SMG tissue sections, n=3 for each tested group. ns: non-significant p>0.05, ****p<0.0001. 554 
Fig 5: Mean ± SEM salivary flow rates of the control (V-C), poly (I:C)-injected (P-PIC), TLR3-blocked (TLR3-555 
I+PIC) and caspase-inhibited ((z-VAD-fmk+PIC)) SMGs. Representative results from 3 independent 556 
experiments. A single i.p injection of z-VAD-fmk, 30 mins prior to poly (I:C) retrograde infusion, preserved saliva 557 
secretion, compared to its complete loss, 9 hrs post infusion of the inflammagen, in the non-treated animals. 558 
Similar functional protection was seen in the glands from mice which received the TLR3/dsRNA competitive 559 
blocker.  560 
Fig 6 A: Scatter plot depicting the RT2 profiler PCR array of Toll Like Receptor pathway genes. The plot gives 561 
an overview of the expression of 84 genes in the control versus poly (I:C)-injected SMGs, 6 hrs P-PIC, from mice 562 
treated and non-treated with z-VAD-fmk. The central line indicates unchanged gene expression; boundaries 563 
represent the two-fold regulation cut-off. In red, up-regulated genes; in green, down regulated genes; and in black, 564 
genes not altered. Blocking the apoptotic signal in the SMGs by pre-treating mice with z-VAD-fmk, reduced the 565 
expression level of all TLR-related genes, compared to the extensive transcriptional upregulation seen in the 566 
SMGs which received poly (I:C) only. One representative experiment presented from three biological repeats. B: 567 
mRNA relative expression of the IFN-response genes: Mx1 and ISG15. Note the extremely significant (p<0.0001) 568 
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decrease in the expression of the tested genes in the glands from z-VAD-fmk-treated animals. Data represents 569 
means ± SEM (n=3). ns: non-significant p>0.05, *P≤0.05, ****p≤0.0001.     570 
Fig 7 A and B (Left): To further confirm the array results, mRNA expression of the pro-inflammatory cytokines 571 
IL-6 and IL-1β were investigated in the SMGs from mice non-treated and treated either with z-VAD-fmk or 572 
TLR3/dsRNA complex inhibitor. The pleiotropic cytokines IL-6 and IL-1 β demonstrated transcriptional 573 
downregulation in response to pan caspase inhibition, ****p<0.0001. (Right): immunohistochemical 574 
representation of IL-6 expression in the SMGs confirmed the inhibiting effect of caspases and TLR3 blockades 575 
on the parenchymally-expressed cytokine (acinar cells: yellow arrow and duct cells: red arrow). Original 576 
magnification = 40x. Western blot analysis of cleaved IL-1β in SMGs from control (V-C) and poly (I:C) (P-PIC) 577 
injected groups, with TLR3/dsRNA complex inhibitor or the caspase inhibitor z-VAD-fmk. Poly (I:C) induced 578 
the expression of the mature IL-1β isoform in the SMGs, which was efficiently abrogated by TLR3 blockade or 579 
pan caspase inhibition. The data are representative of results from three independent experiments. C: 580 
Immunohistochemistry and western blot revealed that pan caspase inhibition remarkably diminished the TLR-3-581 
induced acinar iNOS overproduction (arrows). Bars represent the fold change of iNOS protein levels on the basis 582 
of β-actin and indicate mean values ± SEM (n = 3 in each group). Western blot data are representative of results 583 
from three independent experiments. ns: non-significant p>0.05, *P < 0.05, significant differences between the 584 
V-C and tested groups.  585 
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